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nance versus conversion to Prograf immunoprophylaxis in stable heari transplant recipi- 
ents exhibiting persistent dyslipidemia despite optimal treatment with lipid-lowering 
agents. Methods: One hundred and twenty nine stable heart transplant recipients, aged 
56.7+10.1 years (mean&D) and 77.9i42.2 months post-op. were randomized to con- 
tinue on Neoral (n=64) or switch to Prograf (1x65). Comprehensive lipid profile was mea- 
sured at baseline (bsl)and after I, 3 and 6 months (6 mo). Hemostatic parameters 
(fibrinogen, factor VII. VIII. van Willebrand) and proinflammatory markers (hsCRP, 
homocysteine, slCAM, sVCAM, MCP-I, TPA. PAI-1) were measured at bsl and at 6 mo. 
Results: The Prograf-treated group exhibited a sigmficant greater decrease in total cho- 
lesterol [5.5ltl.l6 (bsl) versus 4.88tl.22 mmol/L. (6 mo): Prograf, versus 5.61+1.36 
(bsl): 5.38iO.87 mmol/L (6 mo): Neoral, p=O.O021]. The Prograf-group also yielded a sig- 
nificant decrease in LDL-cholesterol [3.10+0.8 (bsl) versus 2.72+0.88 mmollL (6 mo); 
p=O.OOS), and cholesterol/HDL ratio 14.73k1.48 (bsl) versus 4.15*1.36 (6 mo) p=O.O17]. 
The decrease in cholesterol was maximum at one month post-switch. For patients 
treated with Prograf. the change in plasma creatinine from baseline to month 6 [mean=- 
6.97t25.291 was significantly greater than for patients who remained on Neoral 
[mean=l.13+19.53] [p=O.O148]. Plasma glucose remains stable in the Prograf-treated 
patients [5.96*1.60 versus 6.01*1.87 mmol/L]. Conclusions: This large prospective con- 
version study showed that Prograf based immunoprophylaxis provides a significant 
decrease in total, LDL-cholesterol and CholesterotlHDL ratio as well as an improvement 
in renal function. These provide a rationale for the use of Prograf in cardiac transplant 
patients with treated but persisting dyslipidemia. 
1156-118 Elevated Soluble Tumor Necrosis Factor Receptor 
Levels in Nonobese Adults With the Atherogenic 
Dyslipoproteinemia 
Robert S. Rosenson, Christine C. Tangney, Daniel Levine, Thomas Parker, Bruce 
Gordon. Northwestern University. The Feinbero School of Medicine. Chicaoo. IL. The 
Rogosin Institute, New York, NY’ 
_ 
Background: Human adipocyte expression and protein levels of TNF-a and TNF recep- 
tor superfamily (TNFRSF) IB are positively correlated with body mass index (BMI) and 
insulin levels, and inversely correlated with adipose tissue lipoprotein lipase activity. In 
this study, we examine the relationships of select inflammatory mediators in the athero- 
genie dyslipoproteinemia (ADL) subjects and the effects of statin therapy on soluble 
TNFRSFs. 
Methods: 60 non-smoking, normoglycemic (HbAlc ~8%) subjects participating in a ran- 
domized 8 week trial comparing statin or placebo. ADL (TG >1.69 mmol/L, HDL-C cl.04 
mmoWL (40 mg/dL) in men and cl.30 mmol/L (50 mg/dL) in women, and/or small LDL 
(40.5 nm) was present in 42 subjects. 
Results: ADL subjects were younger (mean f SD; 49 + 8 YS 54 * 7 y, p=O.O19) and had 
higher levels of both TNF-a (7.9 f 18.1 vs 2.1 * 0.5 ng/mL, p=O.O13) and sTNFRSFlB 
(3.0 * 0.6 vs 2.7 f 0.5 ng/mL, p=O.OSS) compared to the 18 non-ADL subjects. After 
adjustment for age and gender, TNF-n (p=O.O47), sTNFRSFlA (p=O.O50) and 
sTNFRSFlB (p=O.O024) were predictive of ADL. There were no age and gander 
adjusted associations between IL-6 (p=O.O56) or hs-CRP (p=O.O93) and ADL status. Sta- 
tin therapy reduced TNF-a levels more in ADL subjects (7.9 * 18.1 to 6.2 * 11.9 ng/mL, 
p=O.O88) than in non-ADL subjects (2.1 + 0.5 ng/mL to 2.4 * 0.2 ng/mL, p=O.55), 
whereas sTNFRSFlA or sTNFRSFlB levels did not change. 
Conclustons: High levels of TNFa and TNFRSF IA and IB are markers of the proin- 
flammatory state in ADL. 
Predictors of Atherogenic Dyslipoprotenwnra: Multivanate Logistic Regression Analysis 
Overall Classification Overall P-Value 
Accuracy, % for Model 
Age + Gender 67.6 0.022 
Additional adjustment for: 
BMI 65.0 0.084 
TNFa 66.7 0.047 
sTNFRSF1 B 70.0 0.0024 
sTNFRSFlA 61.7 0.050 
IL-6 69.5 0.056 
hs-CRP 66.1 0.093 
sTNFRSFlA + sTNFRSFlB 74.6 0.0038 
sTNFRSF1 B + sTNFRSFlA + basal 66.7 0.047 
TNFa 
sTNFRSF1 B + sTNFRSFlA + IL-6 68.3 0.056 
sTNFRSF1 B + sTNFRSFlA + -hs-CRP 63.3 0.093 
sTNFRSFlA + sTNFRSFlB + TNFa + 66.7 0.037 
IL-6 + hs-CRP 
1156-119 Impact of Multiple Cardiovascular Disease Risk Factors 
on Brachial Artery Distensibility in Young Adults: The 
Bogalusa Heart Study 
Elaine M. Urbina Theda A. Foster, Sathanur R. Srinivasan, Jeffrey Tsai, Gerald S. 
Berenson. Tulane Health Sciences Center, New Orleans, LA, Pulse Metric, Inc., San 
Diego, CA 
Bsckground: Cardiovascular (CV) disease risk factors have been associated with global 
abnormalities in vascular function and structure, as quantified by increased arterial stiff- 
ness. Arterial distensibility decreases with age and the extent of arteriosclerosis. The 
subsequent rise in pulse pressure increases left ventricular work, thereby promoting left 
ventricular hypertrophy, a risk factor for CV morbidity. However, arterrosclerosis may 
affect segments of the vascular tree non-uniformly. The effect of CV risk factors on focal 
areas of the vascular tree is less well studied. Therefore, vascular function in the brachial 
artery and relationships with multiple CV disease risk factors were examined. Methods: 
Brachial artery distensibility was measured using pulse waveform analysis (DynaPulse 
2OOOA Pulse Metric, Inc.) (precision = 0.009543 mmHg-t; coefficrent of variation = 
14.7%; reliability = 0.58). CV risk factors evaluated included serum total and HDL choles- 
terols, serum triglycerides, glucose, body mass Index, and systolic blood pressure. Data 
were collected on 803 young adults from a community-based population (42% male, 
72% white, 19-37 years). Subjects were defined to have an abnormality in risk factor lev- 
els if they ranked in the highest quartile for this population (lowest quartile for HDL). 
Results: Approximately 58% of subjects had elevated levels in one or fewer risk factors, 
18% had clusters of two risk factors, and 24% had clusters of three or more risk factors. 
Results showed distensibility was significantly lower in blacks than in whrtes (0.063 vs. 
0.066 mmHg’ , p<O.M)5). An kwerse linear relationship was found between distensibility 
and the number of risk factors clustering in an individual (pcO.0001 for trend analysis). 
Conclusions: These observations show that clustering of risk factors is assocrated with 
decreased brachial artery distensibility in young adults and non-invasive measures of 
brachial artery funchon are useful in measuring sub-clinical vascular changes related to 
arteriosclerosis. 
1156-152 Acute Effects of Low-Density Lipoprotein Apheresis 
(HELP Procedure) on Cholesterol Oxidation Products 
and Novel Vasoactive Substances Urotensin and 
Relaxin 
Ewa Pulawski, Klaus P. Mellwg, Henning K. Schmidt, Thomas Brinkmann, Knut 
Kleesiek, Dieter Horstkotte, Heart Center North Rhine-Westphalia, Bad Oeynhausen, 
Germany 
Introduction: LDL apheresis according to HELP (APH) is used to treat severe hypercho- 
lesterolemia in patients (pts.) with coronary artery disease. It has been argued that either 
hyperchobsterobmia or extracorporeal treatment may enhance oxidative stress. Our 
study aimed to investigate the influence of a single APH on plasma concentrations (PC) 
of cholesterol oxidation products, urotensln and relaxin in pts. with heterozygous familiar 
hypercholesterolemia and advanced coronary artery disease enrolled in a chronic weekly 
APH. 
Methods: PC of oxidized LDL (oxLDL), superoxide dismutase (Cu/ZnSOD). relaxin and 
urotensin were determined by ELISA, malondialdehyde (MDA) by HPLC, the antioxida- 
tive serum capacity (ImAnOx) by photometric method. Samples of 12 pts. (6 F, 57 y *IO) 
were collected before (pre), immediately after (postl), and prior to the next APH (post2) 
after a week. 
Results: Pts. wth heterozygous familiar hypercholesterolemia showed higher PC of 
oxLDL than healthy controls (n=30). 11.4+6mU/I vs 7.7 mU/I (~~0.05) proportional to 
LDL-chol. (r=0.8, pcO.0601). APH reduced LDL-chol. and oxLDL by 52% and 45%, 
respectively. MDA declined by 30%. Cu/ZnSOD was not changed. Relaxin and uro- 
tensine decreased significantly. 
Conclusions: Single APH reduces cholesterol oxidation products as well as the vaso- 
constrictor urotensin without having an influence on plasma Cu/ZnSOD. The antioxida- 
tive serum capacity tends to decline after APH. 
Pre post 1 pre vs post 1 post 2 pre vs post 2 
OxLDL (mu/L) 11.4+6 6.25+3 p<o.o1 IO*3 n.s. 
MDA (umolll) 1.27iO.3 0.9+0.14 p<O.Ol 1.25kO.2 “.s 
ImAnOx (pmolll) 317*35 287+46 pzo.03 312*29 “.S. 
CU/ZnSOD (ng/ml) 75+36 71+27 n.s. 64220 no. 
Relaxin (pg/ml) 54+52 42244 p<o.o5 50*43 ns. 
Urotensin @g/ml) 40572983 23182656 p<O.OOOl 3636*1092 “.s. 
1156-153 Withdrawal of Statin Treatment Abrogates Its 
Cholesterol-Independent Beneficial Effects in Humans 
Wen-Ter Lai, Kun-Tai Lee, Chin-Sheng Chu, Hsueh-Wei Yen, Wen-Choi Voon, Chi-Hsin 
Hwang, Li-Yu Tsai, Sheng-Hsiung Sheu, Kaohsiung Medical University, Kaohsiung, 
Taiwan,ROC 
Background: Statins exert benificial effects on the vascular wall beyond cholesterol (C) 
lowering. Changes of these pleiotropic effects after discontinuation of statin remained 
unknown. 
Methods: Fourteen patients (8 F, 6 M, 59+17 years) with hypercholesterolemia were 
enrolled. The following 5 sets of serum liprd and 3 serum markers including vascular cell 
adhesion molecule-l(VCAM-I). 6-isoprostane(lS0) and trssue plasmrnogen activa- 
tor(tPA) for each patient were assessed:(l) at baseline; (2) 12 weeks after atovasta- 
tin(A)(lOmg/day); (3) at day I; (4) at day 2; (5) at day 3 after withdrawal of A. 
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Results: The serum C (250.9*38.5 vs.1137.0~24.5mgldl PcO.05) and LDL-C(l70.7*42.2 
vs. 123&18.0mgldl.P<0.05) decreased significantly after A. However, no significant ele- 
vation of C and LDL-C was noted after withdrawal of A. The VCAM-1(592.01+208.31 
~~508.43~178.04 @ml) and the iSO(14.43i8.91 vslO.56+3.31 pgiml) were significantly 
decreased and the tPA( 8.73i3.82 vs. 11.33 * 4.50 @ml) was significantly elevated 
after A. Of note, the VCAM-1 and IS0 were significantly increased to 591.18 * 203.65ngl 
ml and 12.34 * 4.53 ng/ml respectively at day 2 after wthdrawal of A. The tPA decreased 
significantly to 9.98i3.67 nglml at day 3. 
Conclusion: After 12 wks of A, the positwe pleiotropic effects of statln are demonstrated 
simultaneously with lowering the serum C However, after withdrawal of A, these pleiotro- 
pit effects are significantly abrogated withln days and are independent on the elevation 
Of serum c. 
1156-154 Prevalence of Risk Factors for Coronary Disease in 
Myocardial Infarction in the Community 
Francisco Lopez-Jimenez Steven J. Jacobsen, Guy S. Reeder, Susan A. Weston, Jill M. 
Killian, Ryan Meverden, VBronique L. Roger, Mayo Clinic, Rochester, MN 
While reports suggest that the prevalence of cardiovascular risk factors (CV RF) in acute 
myocardial infarction (Ml) may be low. there is a paucity of data on the prevalence of 
modifiable CV RF among patients with Ml in a geographically defined populatton, and it is 
not known whether the prevalence is changing over time. 
OBJECTIVES: To determine the overall prevalence of CV RF among patients with Ml in 
the population and their change over time 
DESIGN: Population-based MI incidence cohort. 
METHODS: We analyzed the prevalence of major modlflabk CV RF including over- 
weight/obesity, history of smoking, diabetes mellitus, hypertension and hyperlipidemia; 
and non-modifiable CV RF including age?75 years, male sex or family history of coronary 
disease among all residents of Olmsted County, MN, hospitalized for a validated incident 
Ml between 1979 and 1998. Demographic and clinical characteristics were collected 
from community medical records. 
RESULTS: During the study period, 2,277 subjects had a Ml. Only 3.6% of patients did 
not have modifiable CV RF. When compared to patients with a Ml from 1979-83, patients 
who had the Ml from 1994-98 were more likely to be overweightiobese. 72% vs. 58%; or 
to have history of hypertension, 61% vs. 50%; or hyperlipidemia, 44% vs. 21%; and less 
likely to have history of smoking, 65% vs. 70%; or to be male, 55% vs. 61%, all with a 
PcO.05 including the four B-year groups. There was no difference in the prevalence of 
diabetes, famtly history of coronary disease or being >75 years old. In patients S65 years 
of age, those who had a Ml from 1994-98 were 72% more likely to be obese (EM1230 Kg/ 
m2) 43% vs. 25%; and either overweight or obese, 82% vs. 70%; and more likely to have 
diagnosis of hyperlipidemia. 47% vs. 29%; but less likely to have history of smoking, 79% 
vs. 89%. than patients who had the MI 15 years earlier. The prevalence of patients with 
24 mafor modifiable CV RF increased from 13% to 22% in the same period. 
CONCLUSIONS: Conversely to what has been reported in other senings, very few 
patients with incident MI in the community do not have any CV RF. The high prevalence 
and average number of modifiable CV RF and their trend in patients with Ml is underscor- 
ing the importance of secondary preventlon after Ml. 
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845-l The Influence of the Metabolic Syndrome on 24-Year 
Mortality Among Middle-Aged Men in the Multiple Risk 
Factor Intervention Trial (MRFIT) 
Jerome D. Cohen. Lynn E Eberly, Ronald Prineas, Gabriela Vasquez, MRFIT Research 
Group, Saint Louis University, St. Louis, MO, Uwersity of Minnesota. Minneapolis, MN 
Background: The Metabolic Syndrome (MS) has been recently defined and identified as 
an Important clustenng of risk factors for cardiovascular disease (CVD). We explored the 
long-term mortality of men with MS and with or without corxurrent untreated diabetes 
mellitus (DM). 
Methods: 12,617 men who participated in the MRFIT were classified according to base- 
line presence of MS and/or DM not on hypoglycemic agents. MS was defined as three or 
more of: body mass index 30+ kg/&, triglycerides 150+ mg/dL, high-density-lipoprotein 
cholesterol ~40 mg/dL. blood pressure 130+ / 85+ mm Hg, and fastmg glucose 1 10+ mgl 
dL. Untreated DM was defined as fasting glucose 126+ mg/dL and not on hypoglycemic 
agents. Proportional hazards regression models were fit for total and CVD mortality with 
adjustment for age, race, cigarette smoking, alcoholic drinks, total cholesterol. uric acid, 
and randomized treatment group (intervention: smoking cessation counseling, dietary 
counseling to lower cholesterol, and hypertension medication; control: usual care by per- 
sonal physician). 
Results: 4,735 men had MS only, 57 had DM only, and 355 had both; 42 men on 
hypcglycemlc agents ware excluded. There were 4,556 total and 2,221 CVD deaths war 
median follow-up of 24.4 years. Average blood pressure was reduced from 135191 mm 
Hg at baseline to 124/82 after 6 years; average cholesterol was reduced from 240 to 231 
mg/dL. Adjusted hazard ratios (HA) for CVD mortality relative to those with neither MS 
nor DM were 1.27 for those with MS only [p<O.OOOl], 1.37 for those with DM only 
[p=O.28], and 1.99 for those with both MS and DM [p-zO.OOOl]. Results were similar for 
total mortality with HAS of 1.15 [p<O.OOOl], 1.63 [p=O.Ol], and 1.68 [p<O.OOOl] respec- 
tively. 
Conclusions: The presence of MS with or without untreated DM was associated with a 
significantly increased risk in mortality compared to those with neither MS nor DM. Thus 
the treatment of MS and its individual components are an important part of the strategy 
for the prevention of CVD. 
10:45 a.m. 
845-2 Niacin Decreases Myocardial Infarction and Total 
Mortality in Patients With Metabolic Syndrome: Results 
From the Coronary Drug Project 
Paul L. Canner, Curl D. Furberg, Michael L. Terrin. Mark E. McGovern, Maryland Medical 
Research Institute, Baltimore, MD, Wake Forest University, Winston-Salem. NC 
Background: In the Coronary Drug Project (CDP), niacin decreased recurrent nonfatal 
myocardial Infarction (NFMI) by 28% at 6 years (study end) and total mortality by 11% at 
15 years (9 years post-trial). Since niacin may affect insulin sensitivity, and new national 
guidelines emphasize the importance of metabolic syndrome (MS), ws evaluated 
whether n&n’s effects on clinical outcomes were similar in patients with and without 
MS. We therefore analyzed results in that subgroup from CDP using National Cholesterol 
Education Program Adult Treatment Panel Ill criteria. 
Methods: We defined MS as at least 3 of: triglycerides $50 mgldL; blood pressure 
~130/>85 mmHg; fasting glucose 2110 but cl26 mg/dL; or body mass index >28 (as a 
substitute for waist circumference). High-density lipoprotein cholesterol (HDL-C) had 
been measured in a small number of patients (N=492), so a second analysis added HDL- 
C < 40 mg/dL as a cnterion for MS. Relative hazards (RH) and Z-values for homogeneity 
of treatment effect between subgroups were computed. 
Results: Results are shown below. The Z-values for ho&geneity indicate no significant 
difference in effect between patients with and without MS. For the subpopulation with 
HDL-C values, event rates overall were: NFMI 8.7% for niacin versus 15.2% for placebo 
(Z = -1.92. RH = 0.55); total mortality, 58.0% for niacin versus 66.1% for placebo (Z = - 
1.69, RH = 0.80). 
Conclusions: We conclude that in the CDP, niacin reduced NFMI and mortality in 
patients both with and without MS. 
Coronary Drug Project Results In Patents With or Without Metabolic Syndrome 
NFMI (6 years) Total Mortality (15 years) 
Analysis Not Including HDL-C 
+MS -MS +MS -MS 
N=563 N=3,343 N=563 N=3,343 
Niacin % 12.2 10.0 58.3 50.9 
Placebo % 16.0 14.0 61.7 57.4 
Relative Hazard 0.75 0.70 0.91 0.83 
Z(homogeneity) 
0.07 0.64 
Analysis including HDL-C 
+MS -MS +MS -MS 
N=124 N=366 N=l24 NC366 
Niacin % a.8 0.7 52.9 59.6 
Placebo % 25.6 11.7 64.4 66.7 
Relatwe Hazard 0.31 0.72 0.73 0.83 
2 (homogeneity) 
-1.74 -0.40 
1 I:00 a.m. 
845-3 The Metabolic Syndrome Is an Independent Predictor of 
Cardiac Events in WOSCOPS Males 
Gilbert J. L’ltalien, Ian Ford, James Shepherd, Bristol Myers-Squibb, Wallingford, CT, 
University of Glasgow, Glasgow, Unlted Kingdom 
Background: The Metabolic Syndrome (METS) is characterized by component condi- 
tions of dyslipldemia, hypertension, insulin resistance, and obesity. Although the syn- 
drome is recognized as a CHD risk equivalent by the ATPIII guidelines committee, there 
